Advertisements
Feeds:
Posts
Comments

Archive for the ‘Academic Publishing’ Category


Dr. Williams Selection of Institutions and Persons of Influence on Life Sciences and Pharma on Twitter.com Blue=Digital Media RED=Follower @pharma_BI

 

Reporter of Number of Followers: Aviva Lev-Ari, PhD, RN

 

Dr. Stephen J. Williams Selection of Institutional and Persons of Influence on Life Sciences and Pharma on Twitter.com Blue=Media RED=Follower @pharma_BI

I @BRCForum British Research Council Twitter forum 245 Founded in 2009, the BioPharma Research Council believes that scientific discourse and debate is central to the research and development process. 245
I @Science2_0 open science forum well followed 4,662 The official site of the 501(c)(3) nonprofit Science 2.0® network – science for the next 2,000 years. 300 million readers and growing.
I @UC3CDL Univ. California Data Curation Center 1,111 University of California Curation Center (UC3) is the digital curation & research data mgmt program at California Digital Library (CDL) @CalDigLib
I @MozOpenLeaders Mozilla Open Science Leaders Forum 2,234 A cohort of Open Leaders fueling the #internethealth movement through training, mentorship & working open best practices. Work Open, Lead Open #WOLO
I @BiotechWkBoston Biotech Week Boston 1,341 #BiotechWeekBoston Where the heart, technology and business of science converge. Join us Sep 4-7, 2018 at Hynes Convention Center.
I @CR_UK Cancer Research UK 327,000 Cancer Research UK pioneers life-saving research to bring forward the day when all cancers are cured.
I @nature Journal Nature 1,900,000 Science news & opinion from the news team at Nature, the international journal of #science. Get our daily newsletter: http://go.nature.com/naturebriefing
I @FierceBiotech fiercebiotech.com 74,800 Tweets by the Fierce Life Sciences editorial team. Subscribe to our daily email newsletter at http://www.fiercebiotech.com/offer/signup  74,800
I @ScienceMagazine @sciencemagazine 1,260,000 The world’s leading outlet for cutting-edge research in all areas of science. Follow @NewsfromScience for stories from our news team.
I @JCNI_NOW Twitter feed of the Journal of the National Cancer Inst.
I @Sagebio SAGE Bionetworks; organization of biocurated networks 4,754 Open Science
I @NCIGlobalHealth NCI reporting Twitter feed 6,058 Global Health news and updates from the National Cancer Institute’s Center for Global Health. Privacy Policy: http://1.usa.gov/oW1EVW  6,058
I @techreview MIT technology report 930,000 Our mission is to make technology a greater force for good by bringing about better-informed, more conscious technology decisions through our journalism.
I @openscience forum for the discussion of open science and open access 60,600 The Open Science Federation is a nonprofit alliance working to improve the conduct and communication of science. We are scientists and citizen scientists, writers, journalists, and educators, and makers of and advocates for Open Data, Open Access, Open Source and Standards, and for diversity, equity, and inclusion in science. Our mission is to open science.
I @WIREDScience WIRED Science blog 2,010,000 Bringing the radiothermally generated heat. The team: @sandraupson, @JetJocko, @rtg0nzalez, @MeganMolteni, and @MrMattSimon. 2,010,000
I @Biotech365 biotech news from over the globe 20,500 Biotech 365 : Biotech and Biopharma news ! #biotech #biotechnology #biopharma#science #pharma #research #pharmaceutical Followers of @pharma_BI 20,500
I @PMWCintl Precision Medicine World Conference 3,720 Leading precision medicine forum hosting the latest initiatives in #healthcare & #biotech, est. 2009 Register for #PMWC20: https://www.pmwcintl.com/registration
P @DrMaurieMarkman Dr. Maurie Markman 2,954 oncologist with wide following due to weekly Twitter discussion on trends in cancer care
P @BLLPHD 1,964 Gene & #CellTherapy Inventor, #Kymriah, CAR #TCell Maker, #Tmunity CoFounder, President-Elect @ISCTGlobal, Eats tweeters for breakfast.
P @weldiery well followed cancer expert on Twitter
P @LifeSciVC 24,300 twitter handle of biotech entrepreneur and VC funder Bruce Booth
Total 6,636,243 2,111,603
I Total 6,607,025 2,111,603
P Total 29,218 0
Advertisements

Read Full Post »


“If the whole world switches to open access since the scholarly community wants this, it would be a world without subscriptions”

Reporter: Aviva Lev-Ari, UC, Berkeley, PhD’83, Editor-in-Chief, PharmaceuticalIntelligence.com – Open Access since 4/2012, 1,585,184 e-Readers, 5,503 articles. @AVIVA1950 is followed by 360 who’s Followers are 2.5 Millions

 

Why did UC decide to end negotiations today?

Elsevier made a new, quite complex, but novel proposal to us at the end of January. On Monday, our negotiating team gave them a written response outlining our appreciation for Elsevier’s effort, but saying that conditions had to be met for us to sign a contract, and that we thought we were pretty far apart. We knew if they couldn’t accommodate us, there was not much point in continuing to negotiate at this time.

Elsevier wanted to keep meeting with us, and we have a meeting scheduled for tomorrow (Friday), but yesterday they approached our faculty directly — faculty who are editors of Elsevier journals, who they have working relationships with — and also the media, and presented a rosy view of the offer they’d made to us. Their characterization of the offer left things out, and they didn’t mention what we’d proposed as conditions. They went public with it. So, we announced the end.

We knew all along it was going to be difficult for Elsevier to change its ways to our satisfaction. We had hoped they’d see the light, that the publishing industry is changing, and that they could help lead the way.

What did each side want the most, and why?

From the very beginning, we had two goals: a reduction in costs — we pay about $11 million a year to Elsevier in subscription fees, which is 25 percent of UC system-wide journal costs — and default open access publication for UC authors: that is, that Elsevier would publish an author’s work open access unless the author didn’t want to. This is consistent with the UC faculty senate’s goal of all work being published open access.

We also wanted a contract that integrated a paid subscription with open access publishing fees. It would have been a transformative agreement, one that would shift payments for reading journal articles into payments for publishing them, and publishing them open access.

Elsevier eventually offered to do something like what we wanted, for open access, but they wanted to charge us a lot more. Our current calculations are that they would have increased the amount of our payments by 80 percent — an additional $30 million over a three-year contract.

Open access would eventually mean fewer subscriptions for Elsevier. But we don’t think they would lose, in the long run, by charging for publishing rather than by charging for reading. The transition the industry is making to open access is a feasible path forward, so that more universities don’t cancel their licenses for the same reasons we did.

If the whole world switches to open access, which we think it will at some point since the scholarly community wants this, it would be a world without subscriptions. But it would be a world where people would still want and need to publish their work in peer-reviewed journals, and there’s always a cost for that.

Doe Library

Berkeley’s University Library was a key player in negotiations with Elsevier. (Photo by J. Pierre Carrillo for the University Library)

Have other universities made the same decision?

In the U.S., we’re the first university system to do this with open access as the main issue.

But all of the universities in Germany canceled two years ago for the same reason. The Max Planck Society (the leading research organization in Germany) also did. The university alliance in Sweden canceled last spring, and the university alliance in Hungary canceled in December. Several other national alliances in Europe are trying to negotiate a similar contract with Elsevier.

Is this a goal of UC, to be a model institution for open access?

SOURCE

https://news.berkeley.edu/2019/02/28/why-uc-split-with-publishing-giant-elsevier/

 

Other related articles published in this Open Access Online Scientific Journal include the following:

University of California accounts for nearly 10% of all published research in the United States. It’s also a significant partner of Elsevier, which publishes about 18% of all UC output and collects more than 25% of the university’s $40-million overall subscription budget.

https://pharmaceuticalintelligence.com/2018/12/09/university-of-california-accounts-for-nearly-10-of-all-published-research-in-the-united-states-its-also-a-significant-partner-of-elsevier-which-publishes-about-18-of-all-uc-o/

Read Full Post »


eScientific Publishing a Case in Point: Evolution of Platform Architecture Methodologies and of Intellectual Property Development (Content Creation by Curation) Business Model

Author: Aviva Lev- Ari, PhD, RN

 

Six demonstrations that justify the claims made in our 2019 VISION:

https://pharmaceuticalintelligence.com/vision/

  • Point #1: Top Author, Chief Scientific Officer, MD, FCAP – share in the Journal’s archive computed
  • Point #2: Top authors by e-Readers per article – A Team at work
  • Point #3: Team members Led by Key Opinion Leader [https://lnkd.in/eEyn69r] generated Intellectual Property (IP) of Three Asset Classes
  • Point #4: Functions and Forms by Asset Class
  • Point #5: SYNERGY among the Three Asset Classes stimulates Value Creation
  • Point #6: Plan for Team membership augmentation and Training under existing Leadership and New Ownership

 

POINT #1: Top Author, Chief Scientific Officer, a retired Chief of Pathology, LHB, MD, FCAP – share in the Journal’s archive computed

Journal archive has 5,486 articles published

LHB has published 1,390 articles = 25.33% – he joined our team with a publication list of +200 articles in referred academic journals. LHB is co-curator of many articles with many of the team members

  • The Young Surgeon and The Retired Pathologist: On Science, Medicine and HealthCare Policy– The Best Writers Among the WRITERS

https://pharmaceuticalintelligence.com/2013/12/10/the-young-surgeon-and-the-retired-pathologist-on-science-medicine-and-healthcare-policy-best-writers-among-the-writers/

 

POINT #2: Top authors by e-Readers per article – A Team at work

Click on this link to review the contributions of Team members who’s articles achieved >1,000 Views.

  • Article Title, Author/Curator’s Name and Article Views >1,000, 4/2012 – 1/2019 @pharmaceuticalintelligence.com

https://pharmaceuticalintelligence.com/2019/01/30/article-title-author-curators-name-and-article-views-1000-4-2012-1-2018-pharmaceuticalintelligence-com/

 

POINT #3: Team members led by Key Opinion Leader (KOL) [https://lnkd.in/eEyn69r] generated Intellectual Property (IP) of Three Asset Classes

 

List of LPBI IP Assets by Asset Class representing a Team Effort

 

  • IP Asset Class I: Launched Open Access Online Scientific Journal @com, 4/2012

https://lnkd.in/erfbayJ

  •  IP Asset Class II: Launched BioMed eSeries, 16-Volumes in Life Sciences and Medicine, 10/2012

BioMed e-Series: 16 Volumes – electronic Table of Contents (eTOCs) of each Volume

https://pharmaceuticalintelligence.com/2017/12/12/biomed-e-series-16-volumes-electronic-table-of-contents-of-each-volume/


Launched 6 Volumes Cardiovascular Diseases e-Series, Bundled on Amazon for $515

https://lnkd.in/e6WkMgF

Launched 10 Volumes in Medicine: Genomics 1,2  Cancer 1,2 Immunology 1,2,3  Precision Medicine 1,2,3,4

https://lnkd.in/ekWGNqA

 

  • IP Asset Class III: Launched Real Time Press Coverage of Biotech Conferences, 3/2013

https://pharmaceuticalintelligence.com/press-coverage/

Part One: The Process of Real Time Coverage using Social Media

Part Two: List of BioTech Conferences 2013 to Present

Part Three: Conference eProceedings DELIVERABLES & Social Media Analytics

 

POINT #4: FUNCTIONS and FORMS by ASSET CLASS

 

LPBI Group’s IP:VENTURE’s Future Potential
IP Asset Class I
https://lnkd.in/erfbayJ
IP Asset Class II
https://lnkd.in/ekWGNqA
IP Asset Class III
https://pharmaceuticalintelligence.com/press-coverage/
Open Access Journal– M1.5 e-Readers,- 5.5K articles- 670 categories,- 7.3K comments- 10K Tags
BioMed E-Series– 16 Volumes- 5 Specialties in Medicine- 6 Volumes Cardiovascular Diseases e-Series, Bundled on Amazon for $515https://lnkd.in/e6WkMgF
Real Time Coverage BioTech/Medicine Conferences– eProceedings- Real Time Tweets on- Two Twitter Handles- Conference Hash Tags@pharma_BI@AVIVA1950- Part Two: List of BioTech Conferences 2013 to Present
Editor-in-Chief’sLeadership:- Senior Editors- Our Team
Our Team’s Product
https://pharmaceuticalintelligence.com/contributors-biographies/
Senior Editors’ Product with Our Team
https://pharmaceuticalintelligence.com/contributors-biographies/senior-editors/https://pharmaceuticalintelligence.com/contributors-biographies/
Editor-in-Chief’s Initiative
https://lnkd.in/eEyn69r
Architecture   Methodologies for ourPlatforms
·       Multi-Authoring Platform – wordpress.com·       Authoring Privilege levels·       Categories of research forming the Journal’s Ontology, a Dynamic Relational and Hierarchical database Multi-Authoring architecture·       Generation of new categories by authors developing the categories they are Owners of·       Article update policy
·       eTOCs design by Editors·       e-Book Style uniformity across all eSeries·       Structure of eBook Parts·       Structure of Chapters·       Structure of Articles·       Commission of Articles Specifically for given e-Books by Editor-in-Chief·       Overarching guidance for e-Books within each eSeries and across eSeries
·       Part One: The Process of Real Time Coverage using Social Media·       Methodology for Conference Coverage using Social Media: 2014 MassBio Annual Meeting 4/3 – 4/4 2014, Royal Sonesta Hotel, Cambridge, MA·       Template Development Process·       Channels of Social Media Development
Business ModelDevelopment: Content Creation by Curation of Scientific Findings
·       Author/Curator initiated article·       Article Commissions by Editor-in-Chief·       Co-Curations·       Research Category Ownership·       e-Books Editors role defined (Job description)
·       e-Books in Kindle Store·       30,000 Oncologists in the US·       40,000 Cardiologists in the US·       All Primary Care Physicians·       All Medical Schools for Curriculum development·       Global market for Medical EducationALL BioMed 16 Volumes [$515+$190+$175+$190+$274 = $1,344]@Amazon BUNDLED 6 Volumes Cardiovascular Diseases for $515https://lnkd.in/e6WkMgF@Amazon UNBUNDLED 10 Volumeshttps://lnkd.in/ekWGNqA·       Genomics 1,2 ($190)·       Cancer 1,2 ($175)·       Metabolomics, Immunology, Infectious Diseases 1,2,3 (#190)·       Precision Medicine 1,2,3,4 ($274)
·       The market is defined as “All Biotech Conferences Organizers around the Globe” in need to own eProceedings for their Conferences for electronic dissemination to conference attendees.·       Digital Archive of Conferences eProceedingsPart Three: Conference eProceedings DELIVERABLES & Social Media Analytics
 
IP Asset Class III
https://pharmaceuticalintelligence.com/press-coverage/
Real Time Coverage BioTech/Medicine Conferences
– eProceedings
– Real Time Tweets on
– Two Twitter Handles
– Conference Hash Tags
@pharma_BI
@AVIVA1950
Part Two: List of BioTech Conferences 2013 to Present
Editor-in-Chief’s Initiative
https://lnkd.in/eEyn69r
·       Part One: The Process of Real Time Coverage using Social Media
·       Methodology for Conference Coverage using Social Media: 2014 MassBio Annual Meeting 4/3 – 4/4 2014, Royal Sonesta Hotel, Cambridge, MA
·       Template Development Process
·       Channels of Social Media Development
·       The market is defined as “All Biotech Conferences Organizers around the Globe” in need to own eProceedings for their Conferences for electronic dissemination to conference attendees.
·       Digital Archive of Conferences eProceedings
Part Three: Conference eProceedings DELIVERABLES & Social Media Analytics

POINT #4 (IN DETAIL): Functions and Forms by Asset Class

 

IP Asset Class I: The Journal

 

The Methodology of Curation for Scientific Research Findings

https://pharmaceuticalintelligence.com/2014/07/30/the-methodology-of-curation-for-scientific-research-findings/

 

>> Evolution of Platform Architecture Methodologies: 

  • Multi-Authoring Platform – wordpress.com
  • Authoring Privilege levels
  • Categories of research forming the Journal’s Ontology, a Dynamic Relational and Hierarchical database Multi-Authoring architecture
  • Generation of new categories by authors developing the categories they are Owners of
  • Article update policy

 

>> Intellectual Property Development (Content Creation by Curation) Business Model 

  • Author/Curator initiated article
  • Article Commissions by Editor-in-Chief
  • Co-Curations
  • Research Category Ownership
  • e-Books Editors role defined (Job description)

 

IP Asset Class II: BioMed e-Series

 

> Evolution of Platform Architecture Methodologies

Cardiovascular Original Research: Cases in Methodology Design for Content Curation and Co-Curation

https://pharmaceuticalintelligence.com/2013/07/29/cardiovascular-original-research-cases-in-methodology-design-for-content-curation-and-co-curation/

  • eTOCs design by Editors
  • e-Book Style uniformity across all eSeries
  • Structure of eBook Parts
  • Structure of Chapters
  • Structure of Articles
  • Commission of Articles Specifically for given e-Books by Editor-in-Chief
  • Overarching guidance for e-Books within each eSeries and across eSeries

 

> Intellectual Property Development (Content Creation by Curation) Business Model 

 

  • e-Books in Kindle Store
  • 30,000 Oncologists in the US
  • 40,000 Cardiologists in the US
  • US & Global markets for Cardiology, Genomics, Cancer, Immunology, Infectious Diseases, Precision Medicine
  • All Primary Care Physicians
  • All Medical Schools for Curriculum development
  • Global market for Medical Education

 

ALL BioMed 16 Volumes [$515+$190+$175+$190+$274 = $1,344]

@Amazon BUNDLED 6 Volumes Cardiovascular Diseases for $515 https://lnkd.in/e6WkMgF

@Amazon UNBUNDLED 10 Volumes in #Medicine https://lnkd.in/ekWGNqA

  • Genomics 1,2 ($190)
  • Cancer 1,2 ($175)
  • Metabolomics, Immunology, Infectious Diseases 1,2,3 (#190)
  • Precision Medicine 1,2,3,4 ($274)

 

Series A – Cardiovascular Diseases – 6 volumes $515

 

Series B – Genomics 1,2  – 2 volumes $190

  • VOLUME 1: Genomics Orientations for Personalized Medicine. On comsince 11/23/2015

http://www.amazon.com/dp/B018DHBUO6

  • VOLUME 2: Latest in Genomics Methodologies for Therapeutics: Gene Editing, NGS & BioInformatics, Simulations and the Genome Ontology

https://pharmaceuticalintelligence.com/biomed-e-books/genomics-orientations-for-personalized-medicine/volume-two-genomics-methodologies-ngs-bioinformatics-simulations-and-the-genome-ontology/

Volume 2 is Work-in-Progress To Be Published in 6/2019 at $115

 

Series C – Cancer & Oncology $175 

  • VOLUME 1 Cancer Biology Genomics

http://www.amazon.com/dp/B013RVYR2K

  • VOLUME 2 Therapies Genomics Interventional Immunotherapy Nanotechnology in Drug Delivery

http://www.amazon.com/dp/B071VQ6YYK

 

Series D – Metabolomics, Immunology, Infectious Diseases $190

  • VOLUME 1 Metabolomics

http://www.amazon.com/dp/B012BB0ZF0

  • VOLUME 2 Infectious Diseases & VOLUME 3 Immunology

https://www.amazon.com/dp/B075CXHY1B

 

Series E Precision Medicine – Four Volumes, Volumes 1,2,3,4 at $274

  • Patients Voices

https://www.amazon.com/dp/B076HGB6MZ

  • Physiology and Therapeutics

https://www.amazon.com/dp/B078313281

  • Medical Discoveries: Genomics Therapeutics

http://www.amazon.com/dp/B019VH97LU

  • 3D #BioPrinting in Medicine for Precision Medicine

https://www.amazon.com/dp/B078QVDV2W

 

IP Asset Class III: Real Time Coverage of BioTech Conferences

 

>> Evolution of Platform Architecture Methodologies

https://pharmaceuticalintelligence.com/2014/04/07/methodology-for-conference-coverage-using-social-media-2014-massbio-annual-meeting-43-44-2014-royal-sonesta-hotel-cambridge-ma/

  • Template Development Process
  • Channels of Social Media Development

 

>> Intellectual Property Development (Content Creation by Curation) Business Model 

  • The market is defined as “All Biotech Conferences Organizers around the Globe” in need to own eProceedings for their Conferences for electronic dissemination to conference attendees.
  • Digital Archive of Conferences eProceedings

 

POINT #5: SYNERGY among the Three Asset Classes stimulates Value Creation

 

  • Concepts from +60 Conferences I covered yielded ~300 new articles, five new per conference, at least
  • Electronic Table of Contents [eTOCs] for each e-Book of the [1,2,3..,16] is derived from the Research categories of the Journal
  • Journal Ontology has 700 Research Categories – knowledge architecture designed by experts
  • Every article in the Journal is connected with Social Media Icons on wordpress.com as an engine for
  1. Pingbacks
  2. New eReaders
  3. Scientists applying to author for the Journal
  4. +7,300 Scientific comments on 5,486 articles published – AGORA  

Electronic Scientific AGORA: Comment Exchanges by Global Scientists on Articles published in the Open Access Journal @pharmaceuticalintelligence.com – Four Case Studies

https://pharmaceuticalintelligence.com/2018/04/10/electronic-scientific-agora-comment-exchanges-by-global-scientists-on-articles-published-in-the-open-access-journal-pharmaceuticalintelligence-com-four-case-studies/

 

POINT #6: Plan for Team membership augmentation and Training under existing Leadership and New Ownership

Work-in-Progress

 

 

Other related articles published in this Open Access Online Scientific Journal include the following: 

 

Innovations in electronic Scientific Publishing (eSP): Case Studies in Marketing eContent, Curation Methodology, Categories of Research Functions, Interdisciplinary conceptual innovations by Cross Section of Categories, Exposure to Frontiers of Science by Real Time Press coverage of Scientific Conferences

https://pharmaceuticalintelligence.com/2017/05/06/case-studies-of-innovations-in-electronic-scientific-publishing-esp-marketing-econtent-curation-methodology-categories-of-research-functions-interdisciplinary-conceptual-innovations-by-cross-sec/

 

e-Scientific Publishing: The Competitive Advantage of a Powerhouse for Curation of Scientific Findings and Methodology Development for e-Scientific Publishing – LPBI Group, A Case in Point

https://pharmaceuticalintelligence.com/2017/06/20/e-scientific-publishing-the-competitive-advantage-of-a-powerhouse-for-curation-of-scientific-findings-and-methodology-development-for-e-scientific-publishing-lpbi-group-a-case-in-point/

 

The Methodology of Curation for Scientific Research Findings

https://pharmaceuticalintelligence.com/2014/07/30/the-methodology-of-curation-for-scientific-research-findings/

 

@PharmaceuticalIntelligence.com – A Case Study on the LEADER in Curation of Scientific Findings

https://pharmaceuticalintelligence.com/2017/06/29/pharmaceuticalintelligence-com-a-case-study-on-the-leader-in-curation-of-scientific-findings/

 

Curation of Scientific Content @Leaders in Pharmaceutical Business Intelligence (LPBI) Group, Boston

https://pharmaceuticalintelligence.com/2016/08/15/curation-of-scientific-content-leaders-in-pharmaceutical-business-intelligence-lpbi-group-boston/

 

Scientific Curation Fostering Expert Networks and Open Innovation: Lessons from Clive Thompson

https://pharmaceuticalintelligence.com/2014/07/17/scientific-curation-fostering-expert-networks-and-open-innovation-lessons-from-clive-thompson-and-others/

 

Cardiovascular Diseases and Pharmacological Therapy: Curations by Aviva Lev-Ari, PhD, RN, 2006 – 4/2018

https://pharmaceuticalintelligence.com/2014/04/17/cardiovascular-diseases-and-pharmacological-therapy-curations-by-aviva-lev-ari-phd-rn/

 

Methodology for Conference Coverage using Social Media: 2014 MassBio Annual Meeting 4/3 – 4/4 2014, Royal Sonesta Hotel, Cambridge, MA

https://pharmaceuticalintelligence.com/2014/04/07/methodology-for-conference-coverage-using-social-media-2014-massbio-annual-meeting-43-44-2014-royal-sonesta-hotel-cambridge-ma/

 

Cardiovascular Original Research: Cases in Methodology Design for Content Curation and Co-Curation

https://pharmaceuticalintelligence.com/2013/07/29/cardiovascular-original-research-cases-in-methodology-design-for-content-curation-and-co-curation/

 

 

 

 

Read Full Post »


Article Title, Author/Curator’s Name and Article Views >1,000, 4/2012 – 1/2019 @pharmaceuticalintelligence.com

 

Reporter: Aviva Lev-Ari, PhD, RN

 

Expert, Author, Writer’s Initials

Name & Bio

Roles

@LPBI Group

LHB Larry Bernstein, MD, FACP,

 

Member of the Board

Expert, Author, Writer – All Specialties of Medicine & Pathology

Content Consultant to Series B,C,D,E

Editor, Series D, Vol. 1, Series E, Vols 2,3,

Co-Editor – BioMed E-Series 13 of the 16 Vols

JDP Justin D. Pearlman, AB, MD, ME, PhD, MA, FACC,

 

Expert, Author, Writer, All Specialties of Medicine, Cardiology and Cardiac Imaging

Content Consultant for SERIES A, Cardiovascular Diseases Co-Editor: Vols 2,3,4,5,6

ALA Aviva Lev-Ari, PhD, RN,

-Ex – SRI, Int’l

-Ex – MITRE

-Ex – McGraw-Hill

Director and Founder

Editor-in-Chief, @pharmaceuticalintelligence.com

Methodologies Developer:

  • Journal Platform Architect,
  • CURATION of Scientific Findings Modules,
  • REALTIME eProceedings Digital 1-Click Publishing

Expert, Author, Writer:

  • Analytics
  • Molecular Cardiology
  • Vascular Biology
TB Tilda Barliya, PhD,

@BIU

Expert, Author, Writer: Nanotechnology for Drug Delivery

Co-Editor, Series C, Vols. 1,2

DN Dror Nir, PhD,

 

Expert, Author, Writer: Cancer & Medical Imaging Algorithms
ZR       
Ziv Raviv, PhD,
@Technion
Expert, Author, Writer: Biological Sciences, Cancer
ZS Zohi Sternberg, PhD, Expert, GUEST Author, Writer

 

Expert, GUEST Author, Writer

Neurological Sciences

SJW Stephen J. Williams, PhD Pharmacology, BSc Toxicology

Ex-Fox Chase

EAW – Cancer Biology

Co-Editor, Series A, Vol.1

Co-Editor, Series B, Genomics: Vols. 1,2

Co-Editor, Series C, Cancer, Vols. 1,2

DS Demet Sag, PhD, CRA, GCP,

 

Expert, Author, Writer: Genome Biology, Immunology, Biological Sciences: Cancer
SS Sudipta Saha, PhD,

 

Expert, Author, Writer: Reproductive Biology, Endocrinology, Bio-Instrumentation

Co-Editor, Series D, Volume 2, Infectious Diseases

AV Aviral Vatsa, PhD, MBBS

 

Expert, Author, Writer: Medical Sciences, Bone Disease, Human Sensation and Cellular Transduction: Physiology and Therapeutics

 

RS Ritu Saxena, PhD,

 

Expert, Author, Writer: Biological Sciences, Bone Disease, Cancer (Lung, Liver)
GST Gail S. Thornton, PhD(c),

Ex-MERCK

Contributing Editor, Author and Medical Writer

Co-Editor, Series E, Vol.1 Voices of Patients

RN Raphael Nir, PhD, MSM, MSc

Ex-ScheringPlough

– Expert, Author, Writer – Member of the Cancer Research Team: Brain Cancer, Liver Cancer, Cytokines

– CSO, SBH Sciences, Inc.

MB Michael R. Briggs, Ph.D.

Ex-Pfizer

– Expert, Author, Writer – Member of the Cancer Research Team: NASH

– CSO, Woodland Biosciences

AK Alan F. Kaul, R.Ph., Pharm.D, M.Sc., M.B.A., FCCP, Expert, Author, Writer

Ex-Director BWH Pharmacy

Expert, Author, Writer: Pharmacology – all aspects of Drug development and dispensation, Policy analyst
AS Anamika Sarkar, PhD,

 

Expert, Author, Writer: Computation Biology & Bioinformatics
MWF Marcus Feldman, PhD,

Stanford University, Biological Sciences, Center for Genomics

751
Research items
51,402
Reads
39,126
Citations
Member of the Board,

Scientific Counsel: Life Sciences,

Content Consultant Series B, Genomics, Vols. 1,2

Co-Editor, Vol. 2, NGS

 

Article Title and Views >1,000,

4/2012 – -1/2018

 

 

 

 

Home page / Archives

Authors

Curators

Reporters

by Name

 

Views

by 

eReaders

 

 

 

 

 

600,145

Is the Warburg Effect the Cause or the Effect of Cancer: A 21st Century View? LHB 16,720
Do Novel Anticoagulants Affect the PT/INR? The Cases of XARELTO (rivaroxaban) and PRADAXA (dabigatran)

JDP

ALA

13,225
Paclitaxel vs Abraxane (albumin-bound paclitaxel) TB 11,872
Recent comprehensive review on the role of ultrasound in breast cancer management DN 11,715
Clinical Indications for Use of Inhaled Nitric Oxide (iNO) in the Adult Patient Market: Clinical Outcomes after Use, Therapy Demand and Cost of Care ALA 7,045
Apixaban (Eliquis): Mechanism of Action, Drug Comparison and Additional Indications ALA 6,435
Mesothelin: An early detection biomarker for cancer (By Jack Andraka) TB 6,309
Our TEAM ALA 6,213
Akt inhibition for cancer treatment, where do we stand today? ZR 4,744
Biochemistry of the Coagulation Cascade and Platelet Aggregation: Nitric Oxide: Platelets, Circulatory Disorders, and Coagulation Effects LHB 4,508
Newer Treatments for Depression: Monoamine, Neurotrophic Factor & Pharmacokinetic Hypotheses ZS 4,188
AstraZeneca’s WEE1 protein inhibitor AZD1775 Shows Success Against Tumors with a SETD2 mutation SJW 4,128
Confined Indolamine 2, 3 dioxygenase (IDO) Controls the Hemeostasis of Immune Responses for Good and Bad DS 3,678
The Centrality of Ca(2+) Signaling and Cytoskeleton Involving Calmodulin Kinases and Ryanodine Receptors in Cardiac Failure, Arterial Smooth Muscle, Post-ischemic Arrhythmia, Similarities and Differences, and Pharmaceutical Targets LHB 3,652
FDA Guidelines For Developmental and Reproductive Toxicology (DART) Studies for Small Molecules SJW 3,625
Cardiovascular Diseases, Volume One: Perspectives on Nitric Oxide in Disease Mechanisms Multiple

Authors

3,575
Interaction of enzymes and hormones SS 3,546
AMPK Is a Negative Regulator of the Warburg Effect and Suppresses Tumor Growth In Vivo SJW 3,403
Causes and imaging features of false positives and false negatives on 18F-PET/CT in oncologic imaging DN 3,399
Introduction to Transdermal Drug Delivery (TDD) system and nanotechnology TB 3,371
Founder ALA 3,363
BioMed e-Series ALA 3,246
Signaling and Signaling Pathways LHB 3,178
Sexed Semen and Embryo Selection in Human Reproduction and Fertility Treatment SS 3,044
Alternative Designs for the Human Artificial Heart: Patients in Heart Failure – Outcomes of Transplant (donor)/Implantation (artificial) and Monitoring Technologies for the Transplant/Implant Patient in the Community

JDP

LHB

ALA

3,034
The mechanism of action of the drug ‘Acthar’ for Systemic Lupus Erythematosus (SLE) Dr. Karra 3,016
VISION ALA 2,988
Targeting the Wnt Pathway [7.11] LHB 2,961
Bone regeneration and nanotechnology AV 2,922
Pacemakers, Implantable Cardioverter Defibrillators (ICD) and Cardiac Resynchronization Therapy (CRT) ALA 2,892
The History and Creators of Total Parenteral Nutrition LHB 2,846
Funding, Deals & Partnerships ALA 2,708
Paclitaxel: Pharmacokinetic (PK), Pharmacodynamic (PD) and Pharmacogenpmics (PG) TB 2,700
LIK 066, Novartis, for the treatment of type 2 diabetes LHB 2,693
FDA Adds Cardiac Drugs to Watch List – TOPROL-XL® ALA 2,606
Mitochondria: Origin from oxygen free environment, role in aerobic glycolysis, metabolic adaptation LHB 2,579
Nitric Oxide and Platelet Aggregation Dr. Karra 2,550
Treatment Options for Left Ventricular Failure – Temporary Circulatory Support: Intra-aortic balloon pump (IABP) – Impella Recover LD/LP 5.0 and 2.5, Pump Catheters (Non-surgical) vs Bridge Therapy: Percutaneous Left Ventricular Assist Devices (pLVADs) and LVADs (Surgical) LHB 2,549
Isoenzymes in cell metabolic pathways LHB 2,535
“The Molecular pathology of Breast Cancer Progression” TB 2,491
In focus: Circulating Tumor Cells RS 2,465
Nitric Oxide Function in Coagulation – Part II LHB 2,444
Monoclonal Antibody Therapy and Market DS 2,443
Update on FDA Policy Regarding 3D Bioprinted Material SJW 2,410
Journal PharmaceuticalIntelligence.com ALA 2,340
A Primer on DNA and DNA Replication LHB 2,323
Pyrroloquinoline quinone (PQQ) – an unproved supplement LHB 2,294
Integrins, Cadherins, Signaling and the Cytoskeleton LHB 2,265
Evolution of Myoglobin and Hemoglobin LHB 2,251
DNA Structure and Oligonucleotides LHB 2,187
Lipid Metabolism LHB 2,176
Non-small Cell Lung Cancer drugs – where does the Future lie? RS 2,143
Biosimilars: CMC Issues and Regulatory Requirements ALA 2,101
The SCID Pig: How Pigs are becoming a Great Alternate Model for Cancer Research SJW 2,092
About ALA 2,076
Sex Hormones LHB 2,066
CD47: Target Therapy for Cancer TB 2,041
Peroxisome proliferator-activated receptor (PPAR-gamma) Receptors Activation: PPARγ transrepression for Angiogenesis in Cardiovascular Disease and PPARγ transactivation for Treatment of Diabetes ALA 2,017
Swiss Paraplegic Centre, Nottwil, Switzerland – A World-Class Clinic for Spinal Cord Injuries GST 1,989
Introduction to Tissue Engineering; Nanotechnology applications TB 1,964
Problems of vegetarianism SS 1,940
The History of Infectious Diseases and Epidemiology in the late 19th and 20th Century LHB 1,817
The top 15 best-selling cancer drugs in 2022 & Projected Sales in 2020 of World’s Top Ten Oncology Drugs ALA 1,816
Nanotechnology: Detecting and Treating metastatic cancer in the lymph node TB 1,812
Unique Selling Proposition (USP) — Building Pharmaceuticals Brands ALA 1,809
Wnt/β-catenin Signaling [7.10] LHB 1,777
The role of biomarkers in the diagnosis of sepsis and patient management LHB 1,766
Neonatal Pathophysiology LHB 1,718
Nanotechnology and MRI imaging TB 1,672
Cardiovascular Complications: Death from Reoperative Sternotomy after prior CABG, MVR, AVR, or Radiation; Complications of PCI; Sepsis from Cardiovascular Interventions JDP

ALA

1,659
Ultrasound-based Screening for Ovarian Cancer DN 1,655
Justin D. Pearlman, AB, MD, ME, PhD, MA, FACC, Expert, Author, Writer, Editor & Content Consultant for e-SERIES A: Cardiovascular Diseases JDP 1,653
Scientific and Medical Affairs Chronological CV ALA 1,619
Competition in the Ecosystem of Medical Devices in Cardiac and Vascular Repair: Heart Valves, Stents, Catheterization Tools and Kits for Open Heart and Minimally Invasive Surgery (MIS) ALA 1,609
Stenting for Proximal LAD Lesions ALA 1,603
Mitral Valve Repair: Who is a Patient Candidate for a Non-Ablative Fully Non-Invasive Procedure? JDP

ALA

1,602
Nitric Oxide, Platelets, Endothelium and Hemostasis (Coagulation Part II) LHB 1,597
Outcomes in High Cardiovascular Risk Patients: Prasugrel (Effient) vs. Clopidogrel (Plavix); Aliskiren (Tekturna) added to ACE or added to ARB LHB 1,588
Diet and Diabetes LHB 1,572
Clinical Trials Results for Endothelin System: Pathophysiological role in Chronic Heart Failure, Acute Coronary Syndromes and MI – Marker of Disease Severity or Genetic Determination? ALA 1,546
Dealing with the Use of the High Sensitivity Troponin (hs cTn) Assays LHB 1,540
Biosimilars: Intellectual Property Creation and Protection by Pioneer and by Biosimilar Manufacturers ALA 1,534
Altitude Adaptation LHB 1,527
Baby’s microbiome changing due to caesarean birth and formula feeding SS 1,498
Interview with the co-discoverer of the structure of DNA: Watson on The Double Helix and his changing view of Rosalind Franklin ALA 1,488
Triple Antihypertensive Combination Therapy Significantly Lowers Blood Pressure in Hard-to-Treat Patients with Hypertension and Diabetes ALA 1,476
IDO for Commitment of a Life Time: The Origins and Mechanisms of IDO, indolamine 2, 3-dioxygenase DS 1,469
CRISPR/Cas9: Contributions on Endoribonuclease Structure and Function, Role in Immunity and Applications in Genome Engineering LHB 1,468
Cancer Signaling Pathways and Tumor Progression: Images of Biological Processes in the Voice of a Pathologist Cancer Expert LHB 1,452
Signaling transduction tutorial LHB 1,443
Diagnostic Evaluation of SIRS by Immature Granulocytes LHB 1,440
UPDATED: PLATO Trial on ACS: BRILINTA (ticagrelor) better than Plavix® (clopidogrel bisulfate): Lowering chances of having another heart attack ALA 1,426
Cardio-oncology and Onco-Cardiology Programs: Treatments for Cancer Patients with a History of Cardiovascular Disease ALA 1,424
Nanotechnology and Heart Disease TB 1,419
Aviva Lev-Ari, PhD, RN, Director and Founder ALA 1,416
Cardiotoxicity and Cardiomyopathy Related to Drugs Adverse Effects LHB 1,415
Nitric Oxide and it’s impact on Cardiothoracic Surgery TB 1,405
A New Standard in Health Care – Farrer Park Hospital, Singapore’s First Fully Integrated Healthcare/Hospitality Complex GST 1,402
Mitochondrial Damage and Repair under Oxidative Stress LHB 1,398
Ovarian Cancer and fluorescence-guided surgery: A report TB 1,395
Sex determination vs. Sex differentiation SS 1,393
LPBI Group ALA 1,372
Closing the Mammography gap DN 1,368
Cytoskeleton and Cell Membrane Physiology LHB 1,367
Crucial role of Nitric Oxide in Cancer RS 1,364
Medical 3D Printing ALA 1,332
Survivals Comparison of Coronary Artery Bypass Graft (CABG) and Percutaneous Coronary Intervention (PCI) / Coronary Angioplasty LHB 1,325
The Final Considerations of the Role of Platelets and Platelet Endothelial Reactions in Atherosclerosis and Novel Treatments LHB 1,310
Disruption of Calcium Homeostasis: Cardiomyocytes and Vascular Smooth Muscle Cells: The Cardiac and Cardiovascular Calcium Signaling Mechanism

LHB

JDP

ALA

1,301
Mitochondrial Dynamics and Cardiovascular Diseases RS 1,284
Nitric Oxide and Immune Responses: Part 2 AV 1,282
Liver Toxicity halts Clinical Trial of IAP Antagonist for Advanced Solid Tumors SJW 1,269
Inactivation of the human papillomavirus E6 or E7 gene in cervical carcinoma cells using a bacterial CRISPR/Cas ALA 1,261
Autophagy LHB 1,255
Mitochondrial fission and fusion: potential therapeutic targets? RS 1,246
Summary of Lipid Metabolism LHB 1,239
Nitric Oxide has a Ubiquitous Role in the Regulation of Glycolysis – with a Concomitant Influence on Mitochondrial Function LHB 1,233
Future of Calcitonin…? Dr. Karra 1,211
Transcatheter Aortic Valve Implantation (TAVI): FDA approves expanded indication for two transcatheter heart valves for patients at intermediate risk for death or complications associated with open-heart surgery ALA 1,197
Gamma Linolenic Acid (GLA) as a Therapeutic tool in the Management of Glioblastoma

RN

MB

1,193
Nanotechnology and HIV/AIDS Treatment TB 1,181
Patiromer – New drug for Hyperkalemia ALA 1,179
‘Gamifying’ Drug R&D: Boehringer Ingelheim, Sanofi, Eli Lilly ALA 1,177
A Patient’s Perspective: On Open Heart Surgery from Diagnosis and Intervention to Recovery Guest Author: Ferez S. Nallaseth, Ph.D. 1,173
Assessing Cardiovascular Disease with Biomarkers LHB 1,167
Development Of Super-Resolved Fluorescence Microscopy LHB 1,166
Ubiquitin-Proteosome pathway, Autophagy, the Mitochondrion, Proteolysis and Cell Apoptosis: Part III LHB 1,162
Atrial Fibrillation contributing factor to Death, Autopsy suggests CEO Dave Goldberg had heart arrhythmia before death ALA 1,159
Linus Pauling: On Lipoprotein(a) Patents and On Vitamin C ALA 1,156
Bystolic’s generic Nebivolol – Positive Effect on circulating Endothelial Progenitor Cells Endogenous Augmentation ALA 1,154
The History of Hematology and Related Sciences LHB 1,151
Heroes in Medical Research: Barnett Rosenberg and the Discovery of Cisplatin SJW 1,146
Overview of New Strategy for Treatment of T2DM: SGLT2 Inhibiting Oral Antidiabetic Agents AV 1,143
Imatinib (Gleevec) May Help Treat Aggressive Lymphoma: Chronic Lymphocytic Leukemia (CLL) ALA 1,140
Issues in Personalized Medicine in Cancer: Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing SJW 1,137
New England Compounding Center: A Family Business AK 1,120
EpCAM [7.4] LHB 1,113
Amyloidosis with Cardiomyopathy LHB 1,110
Can Mobile Health Apps Improve Oral-Chemotherapy Adherence? The Benefit of Gamification. SJW 1,095
Acoustic Neuroma, Neurinoma or Vestibular Schwannoma: Treatment Options ALA 1,089
Treatment of Refractory Hypertension via Percutaneous Renal Denervation ALA 1,088
Proteomics – The Pathway to Understanding and Decision-making in Medicine LHB 1,085
Low Bioavailability of Nitric Oxide due to Misbalance in Cell Free Hemoglobin in Sickle Cell Disease – A Computational Model AS 1,085
Pancreatic Cancer: Genetics, Genomics and Immunotherapy TB 1,083
A NEW ERA OF GENETIC MANIPULATION   DS 1,075
Targeting Mitochondrial-bound Hexokinase for Cancer Therapy ZR 1,074
Normal and Anomalous Coronary Arteries: Dual Source CT in Cardiothoracic Imaging JDP

ALA

1,062
Transdermal drug delivery (TDD) system and nanotechnology: Part II TB 1,057
Lung Cancer (NSCLC), drug administration and nanotechnology TB 1,046
Pharma World: The Pharmaceutical Industry in Southeast Asia – Pharma CPhI 20-22 March, 2013, Jakarta International Expo, Jakarta, Indonesia ALA 1,045
Nitric Oxide and Sepsis, Hemodynamic Collapse, and the Search for Therapeutic Options LHB 1,044
Targeted delivery of therapeutics to bone and connective tissues: current status and challenges- Part I AV 1,044
Press Coverage ALA 1,036
Carbohydrate Metabolism LHB 1,036
Open Abdominal Aortic Aneurysm (AAA) repair (OAR) vs. Endovascular AAA Repair (EVAR) in Chronic Kidney Disease Patients – Comparison of Surgery Outcomes LHB

ALA

1,032
In focus: Melanoma Genetics RS 1,018
Cholesteryl Ester Transfer Protein (CETP) Inhibitor: Potential of Anacetrapib to treat Atherosclerosis and CAD ALA 1,015
Medical Devices Start Ups in Israel: Venture Capital Sourced Locally – Rainbow Medical (GlenRock) & AccelMed (Arkin Holdings) ALA 1,007
The Development of siRNA-Based Therapies for Cancer ZR 1,003

Other related articles published in this Open Access Online Scientific Journal include the following:

FIVE years of e-Scientific Publishing @pharmaceuticalintellicence.com, Top Articles by Author and by e-Views >1,000, 4/27/2012 to 1/29/2018

https://pharmaceuticalintelligence.com/2017/04/28/five-years-of-e-scientific-publishing-pharmaceuticalintellicence-com-top-articles-by-author-and-by-e-views-1000-4272012-to-4272017/

Read Full Post »


Lesson 1 & 2 Cell Signaling & Motility: Lessons, Curations and Articles of reference as supplemental information: #TUBiol3373

Curator: Stephen J. Williams, Ph.D.

UPDATED 2/05/2019

Syllabus for Cell Signaling & Motility for 2019

CELL SIGNALING AND MOTILITY (BIOL 3373)

SPRING 2017

Lectures:

Monday 5:00 PM – 8:00 PM

Biology Life Sciences, Room 342

Instructor:

Antonio Giordano, M.D., Ph.D.

Office hours: Biology Life Sciences Building, Room 431.

Friday: 12:00 noon – 2:00 PM. By appointment

(Phone: 215-2049520, or email: giordano@temple.edu).

Prerequisite:

BIO 3096, Cell Structure and Function (Minimum Grade of C- | May not be taken concurrently). 

Description:

The communication among cells is essential for the regulation of the development of an organism and for the control of its physiology and homeostasis. Aberrant cellular signaling events are often associated with human pathological conditions, such as cancer, neurological disorders, cardiovascular diseases and so on. The full characterization of cell signaling systems may provide useful insights into the pathogenesis of several human maladies.

Text:

Molecular Biology of the Cell 6th Edition, Alberts et al. Garland Science. This textbook is available at the Temple Bookstore.

Grading:

The final grade will be based on the score of four examinations that include both group and individuals assignment. Each exam accounts for 25% of the final grade. There will be no make-up tests during the course. If you have a documented medical excuse and you contact me as soon as possible after the emergency, I will arrange a make-up exam. Complaints regarding the grading will not be considered later than two weeks after the test is returned.

Blackboard:

Announcements will be readily posted on Blackboard. It is your responsibility to check Blackboard periodically.

Attendance: Lecture attendance is mandatory. In addition, punctuality is expected.

Disabilities: Students with documented disabilities who need particular accommodation should contact me privately as soon as possible.

Honesty and Civility:

Students must follow the Temple’s Code of Conduct (see http://www.temple.edu/assistance/udc/coc.htm). This Code of Conduct prohibits: 1. Academic dishonesty and impropriety, including plagiarism and cheating. 2. Interfering or attempting to interfere with or disrupting the conduct of classes or any other activity of the University.”

Academic Rights and Responsibilities:

The policy of the University that regulates Student and Faculty Academic Rights and Responsibilities (Policy # 03.70.02) is available at the following web link: http://policies.temple.edu/getdoc.asp?policy_no=03.70.02

This policy sets the parameters for freedom to learn and freedom to teach, which constitute the pillars of academia.

 

SCHEDULE

This schedule is a general outline, which may be eventually modified. Changes will be announced in advance. Please, always check Blackboard and your email.

Date Topic
Jan 14 Introduction (course overview  and discussion of syllabus). General concepts: Eukaryotic and prokaryotic cell; DNA, RNA  and proteins: Protein synthesis
Jan 21 Martin Luther King, Jr. Day (no classes held)
Jan 28 DNA analysis, RNA analysis; Proteins analysis; Microscopy.
Feb 4 Signaling: general concepts; Introduction to G-proteins; signaling via G-proteins (1)
Feb 11 Exam 1: In class presentation (group assignment)
Feb 18 Signaling via G-proteins (2); tyrosine kinase receptors signaling; Ras-MAPK pathway.
Feb 25 Exam 2: In class presentation (group assignment)
March 4- 10 Spring break
Mar 11

 

Cytoskeleton:  Intermediate filaments; actin
Mar 18 Cytoskeleton: actin binding proteins; microtubules
Mar 25

 

Cytoskeleton: microtubules
April 1

 

Exam 3: in class Multiple choice questions (individual assignment)
Apr 8 Extracellular matrix; cell adhesion; coordinated polarization.
Apr  15 Cell motility and Wnt Signal Signaling. 
Apr  22 Medical consequences of aberrant signaling pathways; production of small molecules for protein kinases In cancer therapy.
Study days
May 6 Exam 4: In class presentation (group assignment)

 

Below is Powerpoint presentations for Lesson 1 and Lesson 2.  Please check for UPDATES on this page for additional supplemental information for these Lessons including articles from this Online Access Journal

 

cell signaling and motility 1 lesson

 

cell signaling and motility 2 lesson

The following articles and curations discuss about the new paradigm how we now envision DNA, in particular how we now understand that the important parts of the genome are not just the exons which code for proteins but also the intronic DNA, which contains all the regulatory elements such as promoters, lnDNA, miRNA sequences etc.  These are good reads for your presentations.

The Search for the Genetic Code

Junk DNA codes for valuable miRNAs

 

And on How the Cell Creates Diversity post the Genetic Code by Use of Post Translational Modifications to Bring Diversity to Protein Structure/Function

Expanding the Genetic Alphabet and Linking the Genome to the Metabolome

Synthetic Biology: On Advanced Genome Interpretation for Gene Variants and Pathways: What is the Genetic Base of Atherosclerosis and Loss of Arterial Elasticity with Aging

Also there is a link to a Blood article using FISH to detect gene amplifications after Gleevec resistance onset here

Novel Mechanisms of Resistance to Novel Agents

Other Articles related to the #TUBiol3373 course include:

Lesson 9 Cell Signaling: Curations and Articles of reference as supplemental information for lecture section on WNTs: #TUBioll3373

Curation of selected topics and articles on Role of G-Protein Coupled Receptors in Chronic Disease as supplemental information for #TUBiol3373

 

Read Full Post »


New website for the Massachusetts Academy of Sciences (MAS)  

http://www.maacadsci.org

 

Who are we? A not-for-profit organization whose prime mission is to increase levels of civic science literacy. Research Scientists across Massachusetts are selected by a governing board as MAS Fellows and a MAS President, based on outstanding accomplishments and willingness to contribute to the mission of MAS.

Mission Statement in Brief: Communicate the value of science to young and mature communities; Contribute to awareness of the promise of science and science policy across the Commonwealth of Massachusetts; Provide opportunity for networking and partnerships across universities and industry, thereby promoting the value of interdisciplinary research and education.

Strategy in Brief: MAS will periodically define themes to focus on and will disseminate information and awareness to the public through workshops and other educational forums led by MAS members, including in public schools, or through university and industry platforms, as well as through on line communication.

Interrelated Research and Education Themes for 2018-2020:

Research: We identify areas of research that cross disciplines, and partner with universities and industry to organize workshops and symposia that connect research and investigators across these entities towards a greater understanding of research, demographic (including of underserved communities) and therapeutic implications.

Education: We aim at increasing awareness of health-focused research on topics, such as obesity and diabetes, particularly to young audiences, and neurodegenerative disease. Education spans from communicative articles written by MAS fellows, to in-person presentations at grade and high schools, to MAS mentoring programs through a STEM Ambassadors Program.

Upcoming and Past Events of Interest

MAS FELLOWS 

 

GOVERNING BOARD

 

ACTIVITIES

Partnerships

Massachusetts Biotechnology Council; Liaison for Scientific & Entrepreneurial Initiatives, Innovation Services

 

Leaders in Pharmaceutical Business Intelligence (LPBI) Group, Boston

 

  • Dissemination of MAS information on established LPBI Group’s digital channels | Link
  • Use of LPBI Group’s BioMed e-Series of 16 books on Amazon.com as frontier contents for Educational curriculum development in Medicine and Life Sciences | Link
  • Open Access Online Scientific Journal – to serve Members of MAS using LPBI Group’s digital channels post publishing | Link

 

New and Past Articles/Books by MAS Members

 

 

 

 

 

DUTIES/BIOS and BY-LAWS

 

MEMBERSHIP & CONTACT US

 

SOURCE

http://www.maacadsci.org

Read Full Post »


Open Access e-Scientific Publishing: Elected among 2018 Nature’s 10 Top Influencers – ROBERT-JAN SMITS: A bureaucrat launched a drive to transform science publishing

Curator: Aviva Lev-Ari, PhD, RN,

Editor-in-Chief, https://pharmaceuticalintelligence.com/

UPDATED by 1/15/2019

Entire editorial board resigns over open access

The editorial board of an influential scientometrics journal — the Journal of Informetrics — has resigned and launched a competing free-to-read journal. The board wanted Elsevier to offer free access to detailed citation data, among other things. “Elsevier needs to be able to continue investing in ways that add value to the research process, which it cannot do if it gives this value away for free,” said the publisher. The former editors have launched a competing free-to-read journal called Quantitative Science Studies.

Nature | 4 min read

2018 Nature’s 10

  • Yuan Cao, Graphene wrangler
  • Viviane Slon, Humanity’s historian
  • He Jiankui, CRISPR rogue
  • Jess Wade, Diversity champion
  • Valérie Masson-Delmotte, Earth monitor
  • Anthony Brown, Star mapper
  • Bee Yin Yeo, Force for the environment
  • Barbara Rae-Venter, DNA detective
  • Robert-Jan Smits, Open-access leader
  • Makoto Yoshikawa, Asteroid hunter

Ones to watch 2019

About Nature’s 10

About the Nature’s 10 image

 

ROBERT-JAN SMITS: Open-access leader: A bureaucrat launched a drive to transform science publishing.

BY HOLLY ELSE

Credit: Artur Eranosian/European Commission

The architect of this year’s bold push to get rid of paywalls in science publishing says he got his ideas from an unlikely source: the publishers themselves.

In March, Robert-Jan Smits was tasked by the European Union’s research commissioner, Carlos Moedas, with a special one-year mission: to get more research papers published outside journal paywalls, and fast. A veteran science-policy bureaucrat, Smits decided to go to the source: he asked big publishers how he could do it. They told him that if the organizations that pay for research insisted the findings had to be published openly, journals would have to adapt.

So that’s what Smits set out to persuade research funders to do — in a plan launched in September that has sent shock waves through science publishing.

Smits has spent decades pulling the science-policy strings at the European Commission, and, until his current assignment, had served eight years as the director-general of research. He was ideally connected to begin rallying Europe’s agencies with the idea, dubbed Plan S for ‘science, speed, solution, shock’, as he puts it. As Nature went to press, 16 funders had signed the plan; they require that the results of work they support be made freely available at the time of publication, starting in 2020.

Publishers have been dictating how research is published for decades, Smits says. “Now it is the funders calling the shots, and we will do things differently.”

It’s too early to know what the ultimate impact of Plan S on research publishing will be. Its details are open for consultation, and much might depend on how many other funders adopt the idea — but it will at least improve access to research, says Peter Suber, director of the Harvard Open Access Project and the Harvard Office for Scholarly Communication in Cambridge, Massachusetts. Smits has been overwhelmed with messages of support. But the initiative has also met with resistance: several publishers have said it could put them out of business, and some researchers have said that they don’t want their choice of where to publish to be restricted.

Smits is no stranger to disrupting the status quo in European science. In 2007, he was instrumental in setting up the excellence-focused European Research Council (ERC) funding agency — when, he says, very few member states wanted it. “We had to go country by country to convince people that we needed it,” he says.

Those who have worked with Smits are not surprised by his ability to get consensus on controversial policies. “Robert-Jan has a fantastic memory, of people, events, documents, policies. His networking capacity is spectacular,” says Helga Nowotny, a former president of the ERC.

Smits’ short tenure as open-access tsar is almost over. Next year, he will leave to become chair of the Eindhoven University of Technology in his native Netherlands. “It’s time for me to leave the commission at what I consider my height,” he says.

SOURCE

https://www.nature.com/immersive/d41586-018-07683-5/index.html?utm_source=Nature+Briefing&utm_campaign=2c80f8d674-briefing-dy-20181218&utm_medium=email&utm_term=0_c9dfd39373-2c80f8d674-43323101

Other Related articles published in this Open Access Online Journal include the following:

University of California accounts for nearly 10% of all published research in the United States. It’s also a significant partner of Elsevier, which publishes about 18% of all UC output and collects more than 25% of the university’s $40-million overall subscription budget.

Reporter: Aviva Lev-Ari, PhD, RN

https://pharmaceuticalintelligence.com/2018/12/09/university-of-california-accounts-for-nearly-10-of-all-published-research-in-the-united-states-its-also-a-significant-partner-of-elsevier-which-publishes-about-18-of-all-uc-o/

‘Plan S’ of Eleven research funders in Europe will make all scientific works free to read as soon as they are published – New policy if adopted could determine the Future of Global Journal Subscription as doomed

 

 

Reporter: Aviva Lev-Ari, PhD, RN

https://pharmaceuticalintelligence.com/2018/10/01/plan-s-of-eleven-research-funders-in-europe-will-make-all-scientific-works-free-to-read-as-soon-as-they-are-published-new-policy-if-adopted-could-determine-the-future-of-global-jou/

 

https://pharmaceuticalintelligence.com/open-access-scientific-journal/

Three Genres in e-Scientific Publishing AND Three Scientists’ Dilemmas

Curator: Aviva Lev-Ari, PhD, RN

https://pharmaceuticalintelligence.com/2017/06/28/three-genres-in-e-scientific-publishing-and-three-scientists-dilemmas/

e-Scientific Publishing: The Competitive Advantage of a Powerhouse for Curation of Scientific Findings and Methodology Development for e-Scientific Publishing – LPBI Group, A Case in Point

Author and Editor-in-Chief: Aviva Lev-Ari, PhD RN

https://pharmaceuticalintelligence.com/2017/06/20/e-scientific-publishing-the-competitive-advantage-of-a-powerhouse-for-curation-of-scientific-findings-and-methodology-development-for-e-scientific-publishing-lpbi-group-a-case-in-point/

Innovations in electronic Scientific Publishing (eSP): Case Studies in Marketing eContent, Curation Methodology, Categories of Research Functions, Interdisciplinary conceptual innovations by Cross Section of Categories, Exposure to Frontiers of Science by Real Time Press coverage of Scientific Conferences

Editor-in-Chief http://pharmaceuticalintelligence.comAviva Lev-Ari, PhD, RN

https://pharmaceuticalintelligence.com/2017/05/06/case-studies-of-innovations-in-electronic-scientific-publishing-esp-marketing-econtent-curation-methodology-categories-of-research-functions-interdisciplinary-conceptual-innovations-by-cross-sec/

FIVE years of e-Scientific Publishing @pharmaceuticalintellicence.com, Top Articles by Author and by e-Views >1,000, 4/27/2012 to 1/29/2018

Editor-in-Chief: Aviva Lev-Ari, PhD, RN

https://pharmaceuticalintelligence.com/2017/04/28/five-years-of-e-scientific-publishing-pharmaceuticalintellicence-com-top-articles-by-author-and-by-e-views-1000-4272012-to-4272017/

 

e-Recognition via Friction-free Collaboration over the Internet: “Open Access to Curation of Scientific Research”

Curator: Aviva Lev-Ari, PhD, RN

https://pharmaceuticalintelligence.com/2013/03/17/e-recognition-via-friction-free-collaboration-over-the-internet-open-access-to-curation-of-scientific-research/

Read Full Post »

Older Posts »